Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
March 20, 2023 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
March 15, 2023 04:00 ET
|
Nouscom Srl
BASEL, Switzerland – 15th March 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new translational...
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
March 09, 2023 07:30 ET
|
SciSparc Ltd
Israeli Ministry of Health granted an approval to use SCI-110 in a clinical trial at the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel TEL AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) --...
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
March 08, 2023 09:00 ET
|
Molecure
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer OATD-02 is an oral, potent and selective dual arginase...
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
March 06, 2023 07:45 ET
|
SciSparc Ltd
TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
February 27, 2023 09:11 ET
|
SciSparc Ltd
The cannabis oil will be used as a part of the Company's proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
February 14, 2023 07:01 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Nemysis Limited Announces Successful IHAT-Gut Trial
February 11, 2023 03:00 ET
|
Nemysis ltd
DUBLIN, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Nemysis is pleased to announce the publication of the successful findings from the IHAT-Gut trial in iron-deficient anaemic patients (NCT02941081) in the...
Mendus AB: Live webcast to discuss clinical results of ADVANCE II trial presented at ASH 2022
December 07, 2022 02:00 ET
|
Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will host a live webcast to review the Company’s most recent clinical results of...
Mendus AB: Direktsänd webbpresentation för att diskutera kliniska resultat från ADVANCE II-studien som presenteras vid ASH 2022
December 07, 2022 02:00 ET
|
Mendus AB
Mendus AB (”Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier som tar sig an tumörrecidiv, kommer att hålla en direktsänd webbpresentation för att gå igenom företagets...